SG Americas Securities LLC Has $158,000 Holdings in Emergent BioSolutions Inc. (NYSE:EBS)

SG Americas Securities LLC increased its holdings in Emergent BioSolutions Inc. (NYSE:EBS) by 171.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 66,011 shares of the biopharmaceutical company’s stock after acquiring an additional 41,712 shares during the period. SG Americas Securities LLC’s holdings in Emergent BioSolutions were worth $158,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Jacobs Levy Equity Management Inc. raised its holdings in shares of Emergent BioSolutions by 0.9% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,246,020 shares of the biopharmaceutical company’s stock worth $4,236,000 after acquiring an additional 11,573 shares during the last quarter. Hsbc Holdings PLC increased its stake in Emergent BioSolutions by 295.4% in the 3rd quarter. Hsbc Holdings PLC now owns 75,133 shares of the biopharmaceutical company’s stock valued at $250,000 after buying an additional 56,129 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in Emergent BioSolutions by 44.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,561,050 shares of the biopharmaceutical company’s stock valued at $5,308,000 after buying an additional 482,632 shares during the last quarter. Values First Advisors Inc. increased its stake in Emergent BioSolutions by 200.0% in the 3rd quarter. Values First Advisors Inc. now owns 152,699 shares of the biopharmaceutical company’s stock valued at $519,000 after buying an additional 101,796 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC increased its stake in Emergent BioSolutions by 51.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 453,565 shares of the biopharmaceutical company’s stock valued at $1,542,000 after buying an additional 153,850 shares during the last quarter. Institutional investors and hedge funds own 78.40% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Benchmark reiterated a “buy” rating and issued a $5.00 price objective on shares of Emergent BioSolutions in a research note on Thursday, April 11th.

Emergent BioSolutions Stock Down 4.1 %

Emergent BioSolutions stock opened at $1.98 on Tuesday. Emergent BioSolutions Inc. has a twelve month low of $1.42 and a twelve month high of $12.01. The firm has a 50 day moving average price of $2.38 and a 200-day moving average price of $2.30. The company has a market capitalization of $103.47 million, a P/E ratio of -0.13 and a beta of 1.20. The company has a quick ratio of 0.54, a current ratio of 1.04 and a debt-to-equity ratio of 0.69.

Emergent BioSolutions (NYSE:EBS) last released its earnings results on Wednesday, March 6th. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.44). Emergent BioSolutions had a negative net margin of 72.11% and a negative return on equity of 37.35%. The company had revenue of $276.60 million for the quarter, compared to the consensus estimate of $247.63 million. During the same period in the prior year, the company earned ($0.31) earnings per share. As a group, equities analysts predict that Emergent BioSolutions Inc. will post -13.98 EPS for the current year.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.